Halofuginone Inhibits the Establishment and Progression of Melanoma Bone Metastases

Patricia Juárez1, Khalid S. Mohammad1, Juan Juan Yin2, Pienrick G. J. Fournier3, Ryan C. McKenna3, Holly W. Davis3, Xiang H. Peng1, Maria Niewolna1, Delphine Javelaud4,5,6,7, John M. Chirgwin1, Alain Mauviel4,5,6,7, and Theresa A. Guise1

Abstract

TGF-β derived from bone fuels melanoma bone metastases by inducing tumor secretion of prometastatic factors that act on bone cells to change the skeletal microenvironment. Halofuginone is a plant alkaloid derivative that blocks TGF-β signaling with antiangiogenic and antiproliferative properties. Here, we show for the first time that halofuginone therapy decreases development and progression of bone metastasis caused by melanoma cells through the inhibition of TGF-β signaling. Halofuginone treatment of human melanoma cells inhibited cell proliferation, phosphorylation of SMAD proteins in response to TGF-β, and TGF-β-induced SMAD-driven transcription. In addition, halofuginone reduced expression of TGF-β target genes that enhance bone metastases, including PTHrP, CTGF, CXCR4, and IL11. Also, cell apoptosis was increased in response to halofuginone. In nude mice inoculated with 1205Lu melanoma cells, a preventive protocol with halofuginone inhibited bone metastasis. The beneficial effects of halofuginone treatment were comparable with those observed with other anti-TGF-β strategies, including systemic administration of SD208, a small-molecule inhibitor of TGF-β receptor 1 kinase, or forced overexpression of Smad7, a negative regulator of TGF-β signaling. Furthermore, mice with established bone metastases treated with halofuginone had significantly less osteolysis than mice receiving placebo assessed by radiography. Thus, halofuginone is also effective in reducing the progression of melanoma bone metastases. Moreover, halofuginone treatment reduced melanoma metastasis to the brain, showing the potential of this novel treatment against cancer metastasis.

Cancer Res; 72(23): 1–10. ©2012 AACR.

Introduction

Melanoma, a malignant tumor that originates in melanocytes, is the sixth most common cancer in the United States (1). The majority of patients with melanoma initially present with localized disease; however, in advanced melanoma, cancer cells metastasize to lungs, liver, brain, and frequently to bone (2). Once melanoma metastasizes to bone, it is incurable. The metastases cause severe pain, fractures, hypercalcemia, nerve compression syndromes, and paralysis (3, 4). Melanoma cells in bone secrete multiple factors that induce osteoclastic bone destruction to release and activate growth factors stored in mineralized bone matrix, which in turn stimulate tumor growth and further bone destruction (5). TGF-β is the major bone-derived factor responsible for driving a feed-forward cycle of cancer metastasis in bone. TGF-β, stored in the bone matrix, is released and activated during osteoclastic bone resorption, and further induces tumor production of osteolytic and prometastatic factors, such as parathyroid hormone–related protein (PTHrP) and interleukin (IL)-11, which stimulate bone destruction, connective tissue growth factor (CTGF) and VEGF-regulating angiogenesis, and the chemokine receptor CXCR4, which causes tumors to home to bone (6, 7). Although TGF-β is a tumor suppressor in normal epithelial cells, it becomes a prometastatic factor in advanced cancer, where it activates the epithelial–mesenchymal transition, tumor cell invasion, angiogenesis, and immunosuppression. Disruption of TGF-β signaling or neutralization of TGF-β-regulated genes in cancer cells decreases bone metastases in preclinical models (8–11).

Melanoma, like other human malignant tumors, secretes large amounts of TGF-β, which in turn promotes resistance to the TGF-β growth inhibitory effects (12–14) and metastatic progression (15, 16). Elevated plasma concentrations of TGF-β are associated with melanoma progression, and high levels of TGF-β2 expression in malignant melanoma correlate with tumor invasion in patients (17, 18). Preclinical studies showed that treatment with the TβRI kinase inhibitor, SD208, caused a reduction in osteolytic bone metastasis and TGF-β-regulated metastatic genes in mice with melanoma and bone metastases.
Overexpression of the TGF-β–signaling inhibitor Smad7 in 1205Lu melanoma cells prevented metastasis to bone in mice, and delayed the establishment and growth of melanoma bone metastases (9). However, the in vitro and animal studies described above have not yet led to clinical application. Indeed, the treatment of metastatic melanoma has not changed substantially in more than a decade, and new strategies are urgently needed.

Halofuginone is a modified plant alkaloid first identified as an inhibitor of fibrosis that decreases type I collagen synthesis (19, 20); it was tested in a recently completed phase II clinical trial in patients with AIDS-related Kaposi sarcoma and showed efficacy to reduce Kaposi sarcoma lesions (21). Halofuginone inhibits TGF-β-dependent phosphorylation of Smad2/3 proteins and increases Smad7 expression (22). We hypothesize that it could be effective against metastatic melanoma. Findings from extensive studies in animal models suggest that halofuginone might be effective for the treatment of cancer and fibrotic diseases. Halofuginone decreased the growth of bladder carcinoma (23), glioma (24), prostate cancer (25), hepatocellular carcinoma (26), Wilms tumor (27), and malignancies of brain (28) and pancreas (29).

Here, we investigated the potential of halofuginone to reduce bone metastases from melanoma in a murine model. Our findings suggest that halofuginone is a promising agent to decrease metastasis of melanoma to bone.

Materials and Methods

Cell culture and reagents
Human 501 mel and 888 mel cells were obtained from and validated by the American Type Culture Collection by DNA profiling. They were grown in RPMI medium supplemented with 10% FBS and antibiotics. Human melanoma cell lines 1205Lu and WM852, derived from WM793 by serial passage through athymic mice and selection of cells metastatic to the lungs, and nodular melanoma metastases, respectively, were a kind gift from Dr. M. Herlyn, Wistar Institute (Philadelphia, PA) and have been previously described (10, 30). They were grown in W489 medium composed of 3 parts MDCB153 and 1 part L15 with 4% FBS and antibiotics. The Smad7 overexpressing clone (1205Lu-Smad7) was described previously (31). Halofuginone (dl-trans-7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidyl)acetonyl]-4(3H)-quinazolinone hydrobromide) was a gift from Intervet Innovation GmbH. Stock solutions for in vitro studies of 2 mg/mL were prepared by dissolving halofuginone in a lactic acid buffer (0.44 mol/L, pH 4.3), and stored at −20 °C (22). For in vivo experiments, halofuginone (1 or 5 μg/0.1 mL) was resuspended in PBS. SD208 was obtained from Scios, Inc. Recombinant human TGF-β1 was purchased from R&D Systems, Inc.

Dual luciferase assay
Melanoma cells were transfected with pGL3-luc constructs (Promega) expressing firefly luciferase either constitutively or under the control of a TGF-β–induced reporter (CAGA)9-luc (32) and with a phRL-CMV plasmid constitutively expressing renilla luciferase (Promega) for normalization. Twenty-four hours later, cells were pretreated with halofuginone for 4 hours, followed by TGF-β1 (5 ng/mL) for 24 hours. Cells were lysed using Passive Lysis buffer (Promega). Luciferase activities were determined using Dual-Luciferase Reporter Assay System (Promega).

Proliferation assay
Cell proliferation was assessed using a colorimetric assay (MTT assay). 1205Lu cells were treated with increasing concentrations of halofuginone (50–300 nmol/L) ± TGF-β (5 ng/mL). Next, MTT reagent (20 μL, 5 mg/mL) was added to each well and incubated for 5 hours at 37 °C followed by a stop buffer (100 μL of HCl 0.01 mol/L-10% SDS) to lyse the cells. Absorbance was measured at 570 nm using a Synergy HT spectrophotometer (Biotek).

Apoptosis assay
Cell apoptosis was evaluated using Annexin V-EGFP Apoptosis Detection Kit (BioVision). Melanoma 1205Lu cells were treated with increasing concentrations of halofuginone (50–300 nmol/L) for 24, 48, or 72 hours. Melanoma 1205Lu cells treated with H2O2 (8 mmol/L) overnight served as a positive control. Cells were trypsinized and counted, and 5 × 105 cells were collected by centrifugation and resuspended in 500 μL of binding buffer. Next, 5 μL of Annexin V-EGFP and 5 μL of propidium iodide (PI) were added and incubated at room temperature for 5 minutes in the dark. Cells were quantified using a FACScalibur flow cytometer (BD Biosciences). Experiments were carried out in triplicate and for each sample and 15,000 events were collected and analyzed using FlowJo software.

Western blot analysis
Cells were pretreated with halofuginone (200 nmol/L) for 4 hours followed by TGF-β1 (5 ng/mL) for 24 hours. Samples were run on 10% SDS-PAGE minigels and transferred onto a Hybond-P membrane (GE Healthcare Life Sciences). Membranes were blocked in TBS-T-milk (5%) for 1 hour, incubated overnight with primary antibody and for 1 hour with secondary antibody. Protein detection was conducted using Western Chemiluminescent HRP substrate (Millipore). Antibodies against Phospho-Smad2 (Ser465/467), Phospho-Smad1 (5 ng/mL) for 24 hours. To total (95°C for 15 s/58°C for 30 s/72°C for 30 s) after an initial 15 minutes incubation at 95°C. Primers were optimized for real-time PCR (amplification efficiency 100 ± 5%). Primer sequences used for the analysis were: PTHrP (sense,
Halofuginone Decreases Melanoma Bone Metastases

5'-ACTGCTCTGCTGGTTAGA-3'; antisense, 5'-GGAGGT-GTCAAGAAGGTGTT-3'; CTFG (sense, 5'-GCTACACATT-TCTCACTTAGAAPCTCA-3'; antisense, 5'-GACAGTCCGTC-AACACATATTGTT-3'); CXCR4 (sense, 5'-CCGTGCAACTG-GTACTTT-3'; antisense, 5'-GTCAAGAAGGTGCTGACC-3'; antisense, 5'- CCTCAGGAAGACTGTCTC-3'). Target gene expression was normalized using housekeeping gene ribosomal protein L32 (RPL32). Samples were analyzed in triplicate and data analyzed using the ΔΔCt method (33).

Animal experiments

Animal experiments were carried out at the University of Virginia (Charlottesville, Virginia). Animal protocols were approved by the Institutional Animal Care and Use Committee and were done in accordance with National and International guidelines.

Intracardiac inoculation of tumor was conducted as previously described (34). Briefly, 1205Lu melanoma cells were resuspended to a final concentration of 10⁶ cells in 100 μL in PBS. Tumor inoculation into the left cardiac ventricle was done on an anesthetized mice positioned ventral side up. Development of osteolytic lesions in mice was followed weekly by radiography using a Faxitron MX-20 with digital camera (Faxitron X-ray Corporation). Lesion area was quantified using the image analysis system MetaMorph software (Universal Imaging Corporation).

Experimental design

Prevention protocol. Female nude mice were divided into 6 groups (n = 15 per group) identified as (i) PBS (vehicle control), (ii) halofuginone 1 μg/mouse/d, (iii) halofuginone 5 μg/mouse/d, (iv) methylcellulose (1%), and (v) SD208 (60 mg/kg/d), according to the respective treatments. Groups 1 to 5 were inoculated with 1205Lu melanoma cells into the left ventricle. Group 6, identified as Smad7, received 1205Lu- Smad7 cells, a stable clone that overexpresses the inhibitory protein Smad7, as previously described (31). All treatments were initiated 2 days before melanoma cell inoculation. PBS and halofuginone treatments (100 μL) were administered daily by intraperitoneal injection. SD208 and its methylcellulose vehicle were administered daily by oral gavage. For survival studies, mice were monitored daily and euthanized when they presented signs of tumor-associated morbidity such as severe loss of body weight, breathing troubles, or paralysis.

Therapeutic protocol. Female nude mice were divided into 3 groups (n = 15 per group) and inoculated in the left ventricle with 1205Lu cells. Osteolytic lesion progression in the hindlimbs of the mice was followed using X-ray. Treatment with PBS (100 μL) or halofuginone (1 or 5 μg/mouse/d) intraperitoneally was initiated after osteolytic lesions were detected (about 13 ± 1 days after the intracardiac inoculation) and continued until the end of the study.

Bone histology and histomorphometry

Hindlimbs were fixed in formalin (10%) for 48 hours, decalcified in EDTA (10%) for 2 weeks, and embedded in paraffin for sectioning. Longitudinal, mid-sagittal sections 3.5 mm in thickness were cut from the tibia and femur using an automated Microm HM 355S microtome (Thermo Fisher Scientific) and stained with hematoxylin and eosin or for TRAP activity to identify osteoclasts. All sections were visualized on a Leica DM LB compound microscope (Leica Microsystems) with a Q-Imaging Micrometer Cools charge-coupled device color digital camera (Vashaw Scientific Inc.). Images were captured and analyzed using BIOQUANT OSTEO software (Image Analysis Corporation). Tumor burden per bone was defined as the area of tibial and femoral bone occupied by cancer cells. Osteoclast number at the tumor/bone interface (OC/mm bone surface) was measured on TRAP-stained slides of femur and tibia at 40× magnification.

Brain and soft tissue histology

In the prevention protocol, brain were collected from 5 mice per group and fixed in 10% buffered formalin. Each brain was cut coronally into 4 quarters and stained for Ki-67, a tumor cell proliferation marker, according to the manufacturer’s instructions (Abcam). We counted clusters of Ki-67-positive tumor cells per total area in the cerebral cortex.

Statistical analysis

Differences between groups were determined by 1-way or 2-way ANOVA followed by Bonferroni posttest. Kaplan–Meier survival curve data were analyzed by log-rank test. All the results were analyzed using GraphPad Prism v4.0 software, expressed as mean ± SEM, and P < 0.05 was considered significant.

Results

Halofuginone inhibits TGF-β signaling in 1205Lu human melanoma cells

The effect of halofuginone on TGF-β signaling was examined using 1205Lu human melanoma cells transfected with TGF-β-induced reporter (CAGA)₉-luc (32), and treated with increasing concentrations of halofuginone in the presence or absence of TGF-β for 24 hours. As shown in Fig. 1A, halofuginone dose dependently inhibited TGF-β-induced promoter activity. Next, we determined by Western blotting the effect of halofuginone pretreatment of 1205Lu cells at 3 different time points (1, 4, and 12 hours) on the phosphorylation of Smad2/3 protein in response to TGF-β. Halofuginone pretreatment by 4 and 12 hours followed by 30 minutes of TGF-β treatment decreased the levels of phosphoSmad2 and phosphoSmad3 levels, whereas total Smad2/3 levels remained unchanged (Fig. 1B). Halofuginone can induce the mRNA expression of the TGF-β signaling inhibitor Smad7 in epithelial and hepatocellular carcinoma cells (22). Thus, we studied the ability of halofuginone to induce expression of Smad7 mRNA in melanoma cells. As shown in Fig. 1C, halofuginone pretreatment of human 1205Lu cells for 4 hours followed by TGF-β treatment for 15 to 60 minutes significantly increased expression of Smad7 mRNA, whereas the higher Smad7 mRNA expression was observed with TGF-β treatment for 45 minutes or longer in the presence of halofuginone.
Halofuginone reduces proliferation and induces apoptosis of 1205Lu human melanoma cells

Halofuginone (50 or 100 nmol/L) significantly reduced the proliferation of 1205Lu cells when compared with untreated cells (Fig. 1D). Treatment with higher doses of halofuginone (200–300 nmol/L) completely prevented cell proliferation. Presence or absence of TGF-β did not change the effect of halofuginone on the proliferation of 1205Lu (Fig. 1D).

To determine whether halofuginone induce apoptosis in 1205Lu melanoma cells, cells where incubated with increasing concentrations of halofuginone (50–300 nmol/L) and a flow cyometric annexin V-PI assay was conducted after 24, 48, and 72 hours. Halofuginone 200 and 300 nmol/L treatments for 48 and 72 hours significantly induced cell death (Fig. 1E).

Halofuginone blocks TGF-β signaling in multiple human melanoma cell lines

We tested the effects of halofuginone in 3 additional TGF-β-responsive human melanoma cell lines: WM852, 501 mel, and 888 mel (13). Halofuginone (200 nmol/L) treatment for 24 hours significantly inhibited TGF-β-induced activity of the (CAGA)₅ promoter in all the melanoma lines analyzed (Fig. 2).

In contrast, halofuginone had no effect on cells transfected with a constitutively active promoter, showing that at the concentration tested, halofuginone was not having nonspecific transcriptional effects. Furthermore, TGF-β–induced Smad2 phosphorylation was decreased by halofuginone treatment in all 3-cell lines (Fig. 2).

Halofuginone reduces mRNA expression of TGF-β–regulated bone metastasis–specific genes

Previous work identified a group of TGF-β–induced genes that promote bone metastasis in breast cancer cells (6) as well as in melanoma cells (9, 10). We examined whether halofuginone can modulate the expression of bone metastasis–specific genes in 1205Lu melanoma cells. TGF-β treatment of 1205Lu cells resulted in the induction of mRNA levels of PTHrP, CTGF, CXCR4, and IL11 (Fig. 3). Meanwhile, cells treated with TGF-β in the presence of halofuginone showed a reduction of mRNA levels of bone metastasis genes compared with TGF-β alone (Fig. 3). Halofuginone–mediated downregulation of the expression of TGF-β–regulated metastatic genes was similar to that of other TGF-β inhibitors including the small-molecule inhibitor of TGF-β receptor 1.
kinase, SD208, or overexpression of the Smad7 inhibitor in 1205Lu-Smad7 cells (Fig. 3).

Preventive treatment with halofuginone reduces osteolytic metastases

To investigate the ability of halofuginone to prevent melanoma bone metastases in vivo, we used nude mice inoculated with 1205Lu melanoma cells into the cardiac left ventricle (9). Two doses of halofuginone (1 or 5 mg/mouse/d) were evaluated in this prevention protocol. Drug treatment started 2 days before intracardiac inoculation of cells and was continued daily throughout the experiment. To compare the efficacy of halofuginone with another inhibitor of the TGF-β signaling pathway and bone metastasis, mice were treated with SD208 (60 mg/kg/day, per os) as well as mice receiving the methylcellulose vehicle. In addition, mice were inoculated with 1205Lu-Smad7 cells that overexpressed the TGF-β signaling inhibitor, Smad7, as a further control. Figure 4A and B shows representative X-ray images of hindlimbs of mice inoculated with 1205Lu cells, the different treatments, and quantification of osteolytic area. Preventive treatment with halofuginone significantly reduced osteolytic lesion area compared with animals treated with PBS in a dose-dependent manner (Fig. 4A–B). As previously reported (10), treatment with SD208 significantly decreased osteolytic lesions compared with vehicle-treated mice to a level comparable to 5 mg of halofuginone. Similarly, overexpression of Smad7 protein protected the mice from developing melanoma bone metastasis, as described previously (9). Treatments with halofuginone or SD208 did not increase the overall survival of the mice (Fig. 4C). However, mice inoculated with 1205Lu cells overexpressing Smad7 had significantly improved survival compared with controls (Fig. 4C).

Halofuginone reduces the progression of established osteolytic bone metastases

Next, we tested the ability of halofuginone to reduce osteolytic metastasis in a therapeutic protocol. Halofuginone was administered after osteolytic lesions were detected on radiographs, 13 days after tumor cell inoculation. Nude mice were then inoculated intraperitoneally daily with PBS or halofuginone (1 or 5 μg/mouse/d). Animals were euthanized at the same time point to compare tumor burden between PBS- and halofuginone-treated groups. Both doses of halofuginone
Cancer Res; 72(23) December 1, 2012

Juárez et al.

Halofuginone decreases brain metastasis of 1205Lu melanoma cells

1205Lu melanoma cells metastasize preferentially to bone, but can also metastasize to other organs, including adrenal glands, lungs, liver, skin, and brain after inoculation into the cardiac left ventricle (9). We visualized 1205Lu cells on brain tissue sections using Ki-67 immunostaining, a marker of proliferating tumor cells. Mice were treated with or without halofuginone (5 μg/mouse/d) or SD208 (60 mg/kg/d) in a preventive protocol. We counted the number of tumor cell clusters per total area.

Halofuginone treatment significantly reduced the number of brain metastases compared with mice treated with vehicle (Fig. 6). In contrast, SD208 treatment did not reduce the number of metastases to the brain, consistent with previous findings that SD208 effects were specific to bone (10).

Discussion

Bone metastases are frequent complications of cancer, occurring in up to 80% of patients with advanced breast or prostate cancer, and in approximately 50% of patients with advanced malignant melanoma (4, 35). TGF-β is a multifunctional cytokine with an established prometastatic role in advanced cancer (36, 37). Blockade of TGF-β function can interrupt multiple events important for the establishment and maintenance of tumors (38, 39).

Previously, we showed that TGF-β plays a key role in the establishment and progression of melanoma bone metastases. The overexpression of TGF-β signaling inhibitor Smad7 (9) or the systemic administration of SD208, the small-molecule inhibitor of TβRI kinase (10), inhibited TGF-β signaling,
thereby reducing expression of TGF-β-regulated metastatic genes and delaying the progression of melanoma–bone metastasis. In this work, we searched for a pharmacologic way to induce the inhibitory molecule Smad7 and focused on halofuginone, a plant alkaloid derivative that blocks TGF-β signaling in epithelial cells by inhibiting the phosphorylation and activation of Smad2 and Smad3, and inducing Smad7 expression (22). Effects of the compound on tumor metastasis to bone have not previously been reported. Here, we show for the first time that halofuginone is effective in an animal model of bone metastasis produced by melanoma.

Inhibition of TGF-β signaling by halofuginone in melanoma cells was shown as follows: (i) dose-dependent reduction of a TGF-β-responsive reporter (CAGA)₉-luc; (ii) inhibition of Smad2/3 phosphorylation induced by TGF-β; (iii) induction of Smad7, an inhibitor of TGF-β signaling, by halofuginone alone and enhanced in the presence of TGF-β; and (iv) inhibition of TGF-β-regulated genes PTHrP, CTGF, CXCR4, and IL-11 that encode for metastatic and osteolytic factors required for the establishment and development of bone metastasis (6). Halofuginone inhibited cell proliferation and induced apoptosis in vitro in a dose- and time-dependent manner. In contrast to myeloma and leukemia cells, where halofuginone induced apoptosis after 48 hours of treatment (40, 41), the effect of halofuginone on 1205Lu melanoma cells was mainly observed after 72 hours. This is consistent with the fact that melanoma 1205Lu cells are often considered more resistant to apoptosis than other cancer cell lines (42, 43). High concentrations of halofuginone did not induce more than 20% of cell death, suggesting that apoptosis is not the sole mechanism of action of halofuginone, yet it may contribute together with inhibition of TGF-β signaling to the experimental therapeutic efficacy of halofuginone against bone metastases.

In a mouse model of bone metastasis, systemic halofuginone treatment reduced the establishment of melanoma bone metastases, significantly reducing osteolytic lesion area.

Figure 4. Preventive treatment with halofuginone reduces osteolytic melanoma bone metastases. A, representative radiography of the hindlimbs of female mice (4 weeks old, n = 12) after intracardiac inoculation of 1205LU cells. Treatment was started 2 days before intracardiac inoculation and continued daily. B, osteolytic lesion area (mm²) was measured on radiographs of hindlimbs of mice with bone metastasis. C, Kaplan–Meyer analysis of mouse survival. *, P < 0.05, Hfg 1 µg/5 µg or Smad7 versus PBS; †, P < 0.05; SD208 versus methylcellulose; ‡, P < 0.05, Hfg 5 µg versus Hfg 1 µg using 2-way ANOVA with Bonferroni posttest.
Halofuginone inhibitory effects on skeletal metastasis of melanoma cells were similar to those of SD208 or Smad7 protein overexpression by a stable cell clone (9, 10). Halofuginone treatment did not improve mouse survival, although in this setting, there was no significant effect on the survival of mice using SD208 treatment. Notably, mice inoculated with cancer cells overexpressing Smad7 protein survived for more than 2 months, as seen in past studies (9), compared with mice treated with halofuginone or SD208, that started dying after 5 weeks. These results suggest that the effect of halofuginone on bone metastases may not be entirely due to Smad7, or that pronounced overexpression of Smad7 in excess of that achieved with halofuginone may have independent effects on tumor metastases. Halofuginone has systemic effects and could induce Smad7 in the host as well as the tumor, whereas Smad7 overexpression in the tumor cells alone may result in tumor cell–specific alterations, which may explain differences in survival.

Indeed, the precise mechanism of action of halofuginone still remains unclear and could involve factors other than Smad7. Roffe and colleagues showed that halofuginone modulates the PI3K/Akt and MAPK/ERK pathways causing the inhibition of Smad3 phosphorylation (44). In mouse models of pancreatic fibrosis and acute promyelocytic leukemia, halofuginone treatment increased N-terminal phosphorylation of c-jun kinase, inhibiting TGF-β signaling and cell proliferation (40, 45). In recent studies, halofuginone activated the amino acid starvation response pathway in vivo, and altered differentiation of T H17 cells (46). Whether halofuginone activates this starvation response in melanoma cells and whether this can affect the development of bone metastases has not yet been studied. Furthermore, T H17 cells have been implicated in tumor immunology and may be a target for cancer therapy. Increased infiltration of IL-17+ T cells correlated with poor survival in patients having hepatocellular carcinoma (47), and IL-17 from T cells protects breast cancer cells from apoptosis and increases metastases (48). However, our experimental model used nude mice lacking T cells. We would need to use a syngeneic model to determine the effect of halofuginone on T H17 and the development of bone metastases.

A highlight of our findings with halofuginone was its ability to reduce tumor growth and tumor progression when bone metastatic lesions were already established. Current therapies for the treatment of bone metastases (e.g., bisphosphonates and anti-RANKL antibody) improve the skeletal morbidity but do not cure or cause regression of the established bone metastases, so more effective therapies are needed. Halofuginone treatment reduced the number of osteoclasts at the tumor–bone interface, which could be due to decreased expression of pro-osteolytic genes by cancer cells treated with halofuginone or to a direct effect of halofuginone on osteoclast and their precursors. TGF-β signaling also stimulates osteoclastogenesis, and inhibitors of TGF-β decrease bone resorption and osteoclast number in normal bone (49). Thus, halofuginone may be beneficial alone or in combination with other bone-targeted antiresorptive therapy.

Halofuginone also reduced melanoma metastasis to the brain, showing that its effects are not limited to bone and bone metastases, unlike the effects of other inhibitors of TGF-β signaling. In mice, disruption of TGF-β signaling with a truncated form of TGF-β type II receptor in breast cancer cells, with overexpression of Smad7 in 1205Lu melanoma cells, or with SD208, a specific inhibitor of TGF-β type 1 receptor kinase domain, did not have anticancer effects outside of bone. Thus, the anticancer effect of halofuginone cannot be explained solely by the inhibition of TGF-β signaling pathway.

In summary, halofuginone inhibits TGF-β signaling and TGF-β–regulated prometastatic genes in vitro. Systemic
administration of halofuginone in a mouse model reduced the establishment of osteolytic bone metastases by melanoma cells. More importantly, halofuginone therapy reduced the progression of established osteolytic bone metastasis in mice, showing its potential as a therapeutic agent. Halofuginone is a novel treatment for metastases that could rapidly be brought to the clinic for the treatment of patients with malignant melanoma.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: P. Juárez, K.S. Mohammad, J.J. Yin, J.M. Chirgwin, A. Mauviel, T.A. Guise
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P. Juárez, P.G.J. Fournier, R.C. McKenna, X.H. Peng, M. Niewolna, T.A. Guise
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P. Juárez, K.S. Mohammad, P.G.J. Fournier, T.A. Guise
Writing, review, and/or revision of the manuscript: P. Juárez, K.S. Mohammad, J.J. Yin, P.G.J. Fournier, J.M. Chirgwin, A. Mauviel, T.A. Guise

Acknowledgments
The authors thank Dr. Hunter Heath III for his valuable comments to improve the quality of the paper.

Grant Support
This work was supported by NIH grants R01CA69158, R01DK067333, and R01DK065831; the Mary Kay Ash Foundation, the V-Foundation, Aurbach Endowment of the University of Virginia, Jerry W. and Peggy S. Throgmartin Endowment of Indiana University, and Indiana Economic Development Fund (T.A. Guise) as well as a grant from the Susan Komen Foundation (P. Juárez and T.A. Guise) and by Ligue Nationale Contre le Cancer (Equipe Labelisée LIGUE E1.2011-AM), INCa (PLBH08-126), a donation from Emile and Henriette Gou tiers, and institutional funding from Institut Curie, INSERM and CNRS (A. Mauviel), and Association pour la Recherche contre le Cancer (D. Javelaud).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 13, 2012; revised August 22, 2012; accepted September 8, 2012; published OnlineFirst September 20, 2012.

References


Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): P. Juárez, K.S. Mohammad, R.C. McKenna, H.W. Davis
Study supervision: K.S. Mohammad, T.A. Guise
Other: Initiation of halofuginone study in melanoma cells, D. Javelaud


Halofuginone Inhibits the Establishment and Progression of Melanoma Bone Metastases

Patricia Juárez, Khalid S. Mohammad, Juan Juan Yin, et al.

Cancer Res  Published OnlineFirst September 20, 2012.

Updated version  Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-1444